|Bid||0.7580 x 900|
|Ask||0.7600 x 1000|
|Day's range||0.7450 - 0.7700|
|52-week range||0.7000 - 8.6900|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||N/A|
|Earnings date||30 Jul 2020 - 03 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||3.33|
Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.
Acorda (ACOR) delivered earnings and revenue surprises of -45.71% and -28.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2020.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its first quarter 2020 update and financial results on Tuesday, May 5 at 4:30 p.m. ET.
Acorda (ACOR) delivered earnings and revenue surprises of 63.41% and 11.88%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anyone researching Acorda Therapeutics, Inc. (NASDAQ:ACOR) might want to consider the historical volatility of the...
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.
Ron Cohen has been the CEO of Acorda Therapeutics, Inc. (NASDAQ:ACOR) since 1995. First, this article will compare CEO...